In this study we report on the correlation between clinical course/treatment response and the detection of the tumor-specific PDGFRA mutations in ctDNA of serially taken blood samples of these 2 patients with GIST, showing the use of mutation detection in ctDNA in plasma to monitor treatment response. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.